Shabir Madhi

He was executive director of South Africa's National Institute for Communicable Diseases from 2011 to 2017, and has served on several WHO committees in roles pertinent to vaccines and pneumonia. In 2018, he co-founded the African Leadership in Vaccinology Expertise (ALIVE) and was appointed Chair of South Africa's National Advisory Group on Immunization (NAGI).
His research has included studies on the pneumococcal conjugate vaccine and rotavirus vaccine, and in pregnant women, the influenza and respiratory syncytial virus vaccines.
Since the global COVID-19 pandemic in 2020, he has been leading COVID-19 vaccine trials in South Africa, including the first in Africa. In 2021 he stated that the first and foremost method of ending COVID-19 in South Africa is to implement a mass vaccination programme. Provided by Wikipedia
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11by Herbert P. Ludewick, Yacine Abed, Nadia van Niekerk, Guy Boivin, Keith P. Klugman, Shabir A. MadhiGet full text
Published 2005-07-01
Article -
12
-
13
-
14
-
15
-
16by Sunday A. Adedini, Dineo Thaele, Matshidiso Sello, Portia Mutevedzi, Cleopas Hywinya, Nonhlanhla Ngwenya, Nellie Myburgh, Shabir A. MadhiGet full text
Published 2021-01-01
Article -
17
-
18
-
19
-
20by Marta C Nunes, Anne von Gottberg, Linda de Gouveia, Cheryl Cohen, Locadiah Kuwanda, Alan S Karstaedt, Keith P Klugman, Shabir A MadhiGet full text
Published 2011-01-01
Article